|
|
| | Deuterated Atazanivir Basic information |
| Product Name: | Deuterated Atazanivir | | Synonyms: | Deuterated Atazanivir;(3S,8S,9S,12S)-3-(1,1-Dimethylethyl)-12-[1,1-di(methyl-d3)ethyl-2,2,2-d3]-8-hydroxy-4,11-dioxo-9-(phenylmethyl)-6-[[4-(2-pyridinyl)phenyl]methyl]-2,5,6,10,13-pentaazatetradecanedioic acid 1,14-di(methyl-d3) ester;DeuteratedAtazanivir-D3-1;CTP-518;CTP 518(Atazanavir, deuterated);CTP-518;CTP518;2,5,6,10,13-Pentaazatetradecanedioic acid, 3-(1,1-dimethylethyl)-12-[1,1-di(methyl-d3)ethyl-2,2,2-d3]-8-hydroxy-4,11-dioxo-9-(phenylmethyl)-6-[[4-(2-pyridinyl)phenyl]methyl]-, 1,14-di(methyl-d3) ester, (3S,8S,9S,12S)-;Atazanavir, deuterated | | CAS: | 1092540-56-1 | | MF: | C38H37D15N6O7 | | MW: | 719.95 | | EINECS: | | | Product Categories: | | | Mol File: | 1092540-56-1.mol |  |
| | Deuterated Atazanivir Chemical Properties |
| storage temp. | Store at -20°C | | solubility | DMSO mg/mL Water mg/mL Ethanol mg/mL | | form | Powder |
| | Deuterated Atazanivir Usage And Synthesis |
| Uses | Atazanavir-d15 is the d15 labled Atazanavir (HY-17367). Atazanavir is a selective HIV-1 protease inhibitor[1]. | | IC 50 | HIV-1 | | References | [1] Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. DOI:10.1177/1060028018797110 |
| | Deuterated Atazanivir Preparation Products And Raw materials |
|